Trial · NCT03008915

Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency

NCT03008915, Phase 2, Completed, Columbia University; results first posted 2021-02-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency. Trials, record NCT03008915. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03008915

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
NCT number: NCT03008915
Status: Completed
Phases: Phase 2
Enrollment: 15 participants, actual
Lead sponsor: Columbia University
Conditions: Alpha-1 Antitrypsin Deficiency, Emphysema, Chronic Obstructive Pulmonary Disease
Interventions: Aspirin, Placebo, Withdrawal from alpha1 antitrypsin replacement therapy
First posted: 2017-01-04
Last updated: 2021-02-17
Results first posted: 2021-02-17

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Pulmonary Microvascular Blood Flow, Mean	2 weeks	Pulmonary microvascular blood flow is measured on contrast-enhanced MRI, limited to blood flow in the 2cm periphery of the lung
Secondary	Endothelial Microparticles	2 weeks	Endothelial microparticles (EMPs) are vesicles shed from endothelial plasma membranes into the circulation in response to endothelial cell perturbation. CD31+ is a measure of apoptotic endothelial microparticles, CD62+ (P-selectin) is a measure of endothelial activation, and Annexin V/CD31+ is a more specific marker of endothelial cell apoptosis.
Secondary	Endothelial Microparticles	5 weeks	Endothelial microparticles (EMPs) are vesicles shed from endothelial plasma membranes into the circulation in response to endothelial cell perturbation. CD31+ is a measure of apoptotic endothelial microparticles, CD62+ (P-selectin) is a measure of endothelial activation, and Annexin V/CD31+ is a more specific marker of endothelial cell apoptosis.
Secondary	Pulmonary Microvascular Blood Flow, Mean	5 weeks	Pulmonary microvascular blood flow is measured on contrast-enhanced MRI in the peripheral 2cm of the lung.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Pulmonary Microvascular Blood Flow, Mean	2 weeks	Due to errors in acquisition of MRI, a number of participants had uninterpretable scans. 13 participants had MRIs interpretable for PMBF on placebo, and 7 on aspirin. Altogether, there were 6 participants with paired results from the two scans.	mL blood/minute per 100mL lung	MEAN
SECONDARY	Endothelial Microparticles	2 weeks	Due to lab closure and technician availability, only the first 3 participants had EMPs measured.	EMPs/uL	MEAN
SECONDARY	Endothelial Microparticles	5 weeks	Only 2 participants had EMPs measured on placebo and 2 off AAT replacement therapy, only 1 participant had EMPs measured at both time points.	EMPs/uL	MEAN
SECONDARY	Pulmonary Microvascular Blood Flow, Mean	5 weeks	2 participants who completed the withdrawal phase had MRIs interpretable for PMBF on placebo and off AAT replacement therapy, data for the other 2 participants was uninterpretable for at least 1 of the 2 scans.	mL blood/minute per 100mL lung	MEAN

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Pulmonary Microvascular Blood Flow, Mean	Aspirin		36.9	Standard Deviation 13.0	mL blood/minute per 100mL lung
Pulmonary Microvascular Blood Flow, Mean	Placebo		35.1	Standard Deviation 15.4	mL blood/minute per 100mL lung
Endothelial Microparticles	Aspirin	CD31+	749.0	Standard Deviation 231.1	EMPs/uL
Endothelial Microparticles	Placebo	CD31+	821.5	Standard Deviation 3.5	EMPs/uL
Endothelial Microparticles	Aspirin	CD62+	1357.3	Standard Deviation 469.6	EMPs/uL
Endothelial Microparticles	Placebo	CD62+	596	Standard Deviation 287.1	EMPs/uL
Endothelial Microparticles	Aspirin	Annexin V, CD31+	145.0	Standard Deviation 62.8	EMPs/uL
Endothelial Microparticles	Placebo	Annexin V, CD31+	317.0	Standard Deviation 210.7	EMPs/uL
Endothelial Microparticles	Off Alpha-1 Replacement Therapy	CD31+	996.0	Standard Deviation 408.7	EMPs/uL
Endothelial Microparticles	Placebo	CD31+	821.5	Standard Deviation 3.5	EMPs/uL

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Treatment 1	STARTED	Aspirin First, Then Placebo	8
Treatment 1	STARTED	Placebo First, Then Aspirin	7
Treatment 1	COMPLETED	Aspirin First, Then Placebo	8
Treatment 1	COMPLETED	Placebo First, Then Aspirin	6
Treatment 1	NOT COMPLETED	Aspirin First, Then Placebo	0
Treatment 1	NOT COMPLETED	Placebo First, Then Aspirin	1
Treatment 2	STARTED	Aspirin First, Then Placebo	8
Treatment 2	STARTED	Placebo First, Then Aspirin	6
Treatment 2	COMPLETED	Aspirin First, Then Placebo	8
Treatment 2	COMPLETED	Placebo First, Then Aspirin	6

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Syncope	Vascular disorders	Aspirin	0	14	0
other	Syncope	Vascular disorders	Placebo	1	15	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Aspirin	0	14
Total, all-cause mortality	Placebo	0	15
Total, other adverse events	Aspirin	0	14
Total, other adverse events	Placebo	1	15
Total, serious adverse events	Aspirin	0	14
Total, serious adverse events	Placebo	0	15

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Aspirin vs Placebo: deaths from any cause	Trial comparisons
Aspirin vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03008915

GET https://conductscience.org/api/trials/v1/NCT03008915/registered

API reference For AI assistants